Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 10/20 | 0.61 |
| ▸ | MAPT | P10636 | 7/20 | 0.61 |
| ▸ | HPGD | P15428 | 5/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.61 |
| ▸ | NPC1 | O15118 | 3/20 | 0.61 |
| ▸ | RAB9A | P51151 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29447058 | 1.00 | ACHE (0.62) | ACHEL3MBTL1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL29080411 | 0.88 | L3MBTL1 (0.55) | ACHEL3MBTL1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL2400792 | 0.83 | TDP1 (0.58) | ACHEL3MBTL1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL30811086 | 0.83 | TDP1 (0.58) | ACHEL3MBTL1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL171783 | 0.81 | ACHE (0.62) | ACHEL3MBTL1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL29634588 | 0.78 | CA12 (0.65) | MAPTHPGDALDH1A1CYP3A4CYP1A2 | |
| SCHEMBL29697819 | 0.78 | MAPK1 (0.65) | L3MBTL1MAPTHPGDSMN1; SMN2TDP1 | |
| SCHEMBL29697785 | 0.78 | MAPT (0.56) | MAPTHPGDSMN1; SMN2TDP1NPC1 | |
| SCHEMBL258418 | 0.78 | CA12 (0.65) | MAPTHPGDALDH1A1CYP3A4CYP1A2 | |
| SCHEMBL811943 | 0.78 | MAPK1 (0.65) | L3MBTL1MAPTHPGDSMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 444 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116554378-A | Non-metallocene catalyst, preparation method and application | 万华化学集团股份有限公司 | 2023-08-08 | — | — | CN | claimed |
| EP-2183239-B1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-08-22 | — | — | EP | claimed |
| US-8153682-B2 | Sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2012-04-10 | — | — | US | claimed |
| EP-2183239-A1 | SULFONAMIDES AS TRPM8 MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2010-05-12 | — | — | EP | claimed |
| US-20090264474-A1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-10-22 | — | — | US | claimed |
| WO-2009012430-A1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-22 | — | — | WO | claimed |
| EP-4665339-A1 | INHIBITING ALPHA V BETA 8 INTEGRIN | Morphic Therapeutic, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12404276-B2 | Substituted pyrrolo[3,4-c]pyrazoles for treating gastric acid-related diseases | SHANGHAI MEDICILON INC. (CN) | 2025-09-02 | — | — | US | disclosed |
| CN-113999232-B | MAT2A inhibitors | 南京正大天晴制药有限公司 | 2025-01-07 | — | — | CN | disclosed |
| WO-2024173570-A1 | INHIBITING αvβ8 INTEGRIN | MORPHIC THERAPEUTIC, INC. (US) | 2024-08-22 | — | — | WO | disclosed |
| WO-2024059472-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2023225661-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-23 | — | — | WO | disclosed |
| EP-2880097-B1 | PROCESS TO PREPARE A VINYL TERMINATED POLYETHYLENE WITH LONG CHAIN BRANCHING | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2023-10-18 | — | — | EP | disclosed |
| EP-0298452-B1 | 2H-1-BENZOPYRANE DERIVATIVES SUBSTITUTED IN POSITION 4 BY ARYL OR N-HETEROARYL | F. HOFFMANN-LA ROCHE AG (CH) | 1993-06-30 | — | — | EP | disclosed |
| US-5118694-A | Hypotensive agents; treatment for cardiovascular and muscular disorders | HOFFMANN-LA ROCHE INC. (US) | 1992-06-02 | — | — | US | disclosed |
| EP-0447602-A2 | Melt processable thermotropic aromatic copolyesters and process for preparing same | THE DOW CHEMICAL COMPANY (US) | 1991-09-25 | — | — | EP | disclosed |
| US-4971982-A | HYPOTENSIVE AGENTS, CARDIOVASCULAR DISORDERS, SMOOTH MUSCLE DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1990-11-20 | — | — | US | disclosed |
| EP-0298452-A2 | 2H-1-benzopyrane derivatives substituted in position 4 by aryl or N-heteroaryl | F. HOFFMANN-LA ROCHE AG (CH) | 1989-01-11 | — | — | EP | disclosed |
| US-4376077-A | BLUE GREEN COLOR FOR NYLON | SANDOZ LTD. (CH) | 1983-03-08 | — | — | US | disclosed |
| US-4218567-A | Process for aromatic ethers | HOFFMANN-LA ROCHE INC. (US) | 1980-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404276-B2 | Substituted pyrrolo[3,4-c]pyrazoles for treating gastric acid-related diseases | GIPR, PGC, GRPR | ACHE 4867/4885L3MBTL1 4318/4885MAPT 3777/4885 |
| US-20090264474-A1 | SULFONAMIDES AS TRPM8 MODULATORS | TRPM8, TRPM5, TRPM2 | ACHE 1006/4885L3MBTL1 3261/4885MAPT 3324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.